	5-year overall survival,	
Genotype	No. (%)	RR of death† (95% CI)
Promoter SNP		
mbl2_11 (rs11003125)	215 (41.1)	
C/C ( <i>L/L</i> )	238 (45.5)	1.0 (referent)
C/G ( <i>L/H</i> )	70 (13.4)	0.86 (0.65 to 1.15)
G/G ( <i>H/H</i> )		1.43 (0.99 to 2.07)
mbl2_12 (rs7096206)	329 (61.7)	
G/G(Y/Y)	180 (33.8)	1.0 (referent)
G/C(Y/X)	24 (4.5)	0.59 (0.45 to 0.79)
C/C $(X/X)$	204 (38.3)	0.81 (0.44 to 1.50)
$G/C + C/C^{\dagger}$		0.62 (0.47 to 0.81)
Exon 1 SNP		
mbl2_03 (rs5030737)		
C/C (Non-D/Non-D)	447 (85.0)	1.0 (referent)
C/T (Non-D/D)	75 (14.2)	0.94 (0.66 to 1.35)
T/T $(D/D)$	4 (0.8)	2.60 (0.64 to 10.66)
mbl2_01 (rs1800450)		
G/G (Non-B/Non-B)	391 (75.5)	1.0 (referent)
G/A (Non-B/B)	120 (23.2)	0.84 (0.62 to 1.14)
A/A $(B/B)$	7 (1.3)	2.45 (0.90 to 6.70)
mbl2_02 (rs1800451)		
G/G (Non-C/Non-C)	479 (97.0)	1.0 (referent)
G/A ( <i>Non-C/C</i> ))	14 (2.8)	0.91 (0.37 to 2.22)
A/A ( $C/C$ )	1 (0.2)	_
Haplotype§	,	
GGCGG (HYA)	294 (28.6)	1.0 (referent)
CGCGG (LYA)	280 (27.3)	1.03 (0.82 to 1.31)
CCCGG (LXA)	220 (21.4)	0.71 (0.54 to 0.92)
CGCAG (LYB)	135 (13.2)	0.90 (0.67 to 1.21)
CGCGA (LYC)	16 (1.6)	0.75 (0.31 to 1.84)
GGTGG (HYD)	81 (7.9)	0.95 (0.67 to 1.36)
Diplotype		(,
YA/YA	159 (31.0)	1.0 (referent)
YA/XA	124 (24.2)	0.66 (0.46 to 0.95)
XA/XA	23 (4.5)	0.84 (0.44 to 1.58)
YA/B	78 (15.2)	0.95 (0.65 to 1.39)
XA/B	30 (5.8)	0.38 (0.19 to 0.74)
YA/C	8 (1.5)	1.25 (0.45 to 3.43)
YA/D	46 (9.0)	0.91 (0.57 to 1.45)
XA/D	17 (3.3)	0.57 (0.26 to 1.23)
XA/C	3 (0.6)	<u> </u>
O/O	25 (4.9)	1.02 (0.55 to 1.88)

<sup>\*</sup>RR = risk ratio; CI = confidence interval; SNP = single-nucleotide polymorphism; — = insufficient data. Statistically significant associations are in boldface type.

<sup>†</sup>Risk ratio of death was adjusted for sex, stage (III–IV vs. I–II), age at diagnosis, current smoking status, and pack-years of smoking.

<sup>‡</sup>A dominant model was assumed.

<sup>‡</sup>SNPs are ordered in the haplotypes by location on the gene, as L/H, Y/X, A/D, A/B, and A/C.